Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, ...

Series A financing led by 4BIO Capital, with major new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio ...

Series A financing led by 4BIO Capital, with major new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, supported by existing investors Abingworth and ...

Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program today to enable cell therapy developers to ...

Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance the lead program CYT-X300 to the ...

Bracco's new BubbleGen technology streamlines cell therapy manufacturing for one-step cell separation and activation with no magnetic residuals BubbleGen microbubbles can target specific cell ...

Cytospire Therapeutics was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of ...

BIO Capital joined by new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, ...

WALTHAM, MA - April 23, 2026 - - KACTUS has published a technical framework for engineering 2+1 and trispecific T-cell engager therapeutics, addressing structural scaffold challenges for drug ...

Cytospire Therapeutics raises £61M in Series A funding to advance innovative cancer immunotherapy targeting gamma delta T ...

Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...

After a disappointing phase 1 showing, Janux Therapeutics is kicking one of its bispecific T-cell engagers (TCEs) ...